[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"arrythmia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:arrythmia":473},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,18,0,[8,43,73,101,131,177,201,228,249,281,300,320,339,365,387,404,427,450],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100427656",false,"NCT04848844","The PAtients pResenTing With COngenital HeaRt DIseAse Register (ARTORIA-R)","The PAtients pResenTing With COngenital HeaRt DIseAse Register (ARTORIA-R): A Global Register to Investigate Factors Associated With Morbidity and Mortality in Adult Patients With Congenital Heart Disease (ACHD) on the Waiting List for Heart or Heart\u002FLung Transplantation","ARTORIA-R","Inclusion Criteria:\n\n1. The patient has to be listed as an adult transplant candidate in the country the data is obtained with an age ≥18 years\n2. The patient has to have a congenital heart defect or an inherited cardiomyopathy (specific; hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy or non-compaction cardiomyopathy) which is often included into the category ACHD\n3. Data is obtained from the first evaluation for listing or listing for heart-only or heart-combined organ transplantation\n4. Transfer of anonymised data\n5. The institution\u002Forganization agrees to the memorandum how data is managed, and scientific cooperation is planned between all institutions\n\nExclusion Criteria:\n\na. The patient is listed for a second heart transplantation (retransplantation)","ALL","18 Years",{"count":19,"type":20},2000,"ESTIMATED","30 Years","OBSERVATIONAL","Advances in surgical and medical care have led to improved outcomes in patients with congenital heart disease (CHD). As a consequence, the majority of patients nowadays survives to adulthood (adults with CHD, that is, adult CHD \\[ACHD\\]) with good quality of life. Despite the surgical success, the morbidity and mortality of ACHD is higher than in the general population and is linked to the development of heart failure (HF) in adulthood.\n\nHF occurs in approximately 25% of patients with ACHD, even in those patients in whom the congenital mal-formation has been corrected successfully in childhood. The time course and presentation are heterogeneous owing to variable congenital malformation and limitation of treatment options. ACHD with an anatomic right ventricle as the systemic ventricle (e.g., atrial switch operation in patients with transposition of the great arteries \\[TGAs\\]) and those with a functional single ventricle (e.g., Fontan circulation) appear to be at higher risk of developing HF. Young age at initial corrective surgery-often in the first 2 years of life-and lack of specific medical therapies can contribute to a high and early demand for heart transplantation in patients with ACHD.",[25,26,27,28,29],"Congenital Heart Disease","Heart Failure","Transplant; Complication, Failure","Arrythmia","Ventricular Dysfunction","RECRUITING","2026-06-28",{"date":33,"type":34},"2026-07-01","ACTUAL",{"date":36,"type":34},"2020-09-02",{"date":38,"type":20},"2030-07-30",{"name":40,"class":41},"Universitätsklinikum Hamburg-Eppendorf","OTHER",1,{"id":44,"slug":4,"hasResults":10,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":10,"sex":16,"minAge":49,"maxAge":17,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":42},"100559457","NCT06564376","Tailored MgSO4 Supplementation to Reduce Complications in Pediatric Heart Surgery","Individually Tailored MgSo4 Supplementation to Reduce Cardiac and Renal Complications in Pediatric Heart Surgery","Inclusion Criteria:\n\n* Children undergoing cardiac surgery utilizing cardiopulmonary bypass\n\nExclusion Criteria:\n\n* Children undergoing cardiac surgery without cardiopulmonary bypass\n* Children with Renal disease\n* Children with pre-existing arrhythmia\n* Children on anti-arrhythmia medication","0 Years",{"count":51,"type":20},96,"INTERVENTIONAL",[54],"NA","Lay Summary\n\nThis study tests two ways of measuring blood magnesium after heart surgery. Children who need heart surgery may have heart and kidney problems after surgery. The right amount of magnesium in blood reduces this risk. This study will test the best way to measure magnesium. This will let doctors choose the right dose of MgSO4. MgSO4 is a magnesium supplement. Taking MgSO4 after heart surgery helps children. For each child, it is best to personalize MgSO4 dose. This is based on the amount of magnesium in blood. This study will test two ways of personalizing MgSO4 dose.\n\nIn the blood, there are two kinds of magnesium. Usually, blood magnesium tests measure both forms together. This does not say anything about active magnesium. This study will measure the two forms separately. Then, MgSO4 will be given based on either the active or whole magnesium. Measuring active magnesium is good. Active magnesium levels change faster than total. That means active magnesium tests may better protect children. Also, active magnesium has more of an impact on heart and kidney function. Focusing on the active form will help these organs stay healthy.\n\nTo test how well the MgSO4 is working, heart and kidneys will be examined. After surgery, certain harmful heart rhythms can occur. The types and number of harmful rhythms will be studied. Kidney problems can also happen after heart surgery. Kidney health will be studied. To help understand how active magnesium works, further tests will be done. These tests will look for evidence of poor health in the cells that make up the heart, kidney, and blood.",[57,28,25],"AKI - Acute Kidney Injury",[59,60,61,62],"Acute Kidney Injury","Arrhythmias","Congenital heart surgery","Cardiopulmonary bypass","NOT_YET_RECRUITING","2026-06-12",{"date":66,"type":34},"2026-06-16",{"date":68,"type":20},"2026-08-01",{"date":70,"type":20},"2029-06",{"name":72,"class":41},"West Virginia University",{"id":74,"slug":4,"hasResults":10,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":81,"conditions":82,"keywords":85,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":42},"100511097","NCT05935007","Aveir DR Real-World Evidence Post-Approval Study","Aveir Dual-Chamber Leadless Pacemaker Real-World Evidence Post-Approval Study","Eligibility Criteria:\n\n* Implanted with an Aveir DR leadless pacemaker\n* Continuous enrollment in Medicare Part A and Part B for 12 months prior to implant and for -30 days after implant, except in the case of death within the 30-day period\n* Ability to link with Medicare fee-for-service data",{"count":80,"type":20},1805,"The purpose of this post-approval study is to evaluate the long-term safety of the dual-chamber Aveir DR leadless pacemaker using real-world evidence methods.",[83,28,84],"Cardiac Pacemaker","Bradycardia",[86,87,88,89,90],"bradycardia","sick sinus rhythm","pacemaker","av block","vasovagal syncope","2026-05-18",{"date":93,"type":34},"2026-05-20",{"date":95,"type":34},"2023-10-31",{"date":97,"type":20},"2030-12-31",{"name":99,"class":100},"Abbott Medical Devices","INDUSTRY",{"id":102,"slug":4,"hasResults":10,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":106,"eligibilityCriteria":107,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":108,"targetDuration":4,"studyType":52,"phases":110,"briefSummary":111,"conditions":112,"keywords":117,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":130},"100633062","NCT07521800","Remote ECG Monitoring Post TAVI","Remote ECG Monitoring as a Diagnostic Tool for Therapeutic Strategies After Transcatheter Aortic Valve Replacement: Rationale and Design of the DRAGON-TAVI Trial.","DRAGON-TAVI","Inclusion Criteria:\n\n* Patient age over 18 years old\n* Severe aortic stenosis\n* Moderate or high cardiovascular risk based on current ESC Guidelines \"Heart Team\" qualification for TAVI\n* Written informed consent of the patient for participation in the study\n\nExclusion Criteria:\n\n* History of atrial fibrillation or atrial flutter\n* Previously known conduction disturbances\\*\\*\n* Presence of: pacemaker, CRT-P, ICD, CRT-D before or after TAVI\n* Ischaemic stroke, TIA, MI or heart surgery within 1 month before TAVI qualification\n* Haemorrhagic stroke within 1 year before TAVI qualification\n* Chronic immunosuppressive therapy\n* Comorbidities (e.g. drug addiction, alcohol abuse, emotional\u002Fmental disorders) which do not allow safe participation in the study",{"count":109,"type":20},250,[54],"The DRAGON TAVI study is a multicenter, prospective, open, randomised trial, which will enrol 250 patients, randomized 1:1 to the study group (continuous 30-day ECG monitoring with visits triggered by ECG findings) and standard care (ie. control group, which will receive the standard post op 24-48h ECG monitoring and a regular follow-up visit with standard ECG within 30 days). The duration of the study is 12 months ± 1 month.",[113,114,28,115,116],"TAVI(Transcatheter Aortic Valve Implantation)","Remote Monitoring","Atrial Fibrillation (AF)","Atrioventricular Block",[118,119,120],"TAVI","ECG","Monitoring","2026-04-07",{"date":123,"type":34},"2026-04-13",{"date":125,"type":34},"2023-12-01",{"date":127,"type":20},"2028-02-01",{"name":129,"class":41},"Medical University of Silesia",4,{"id":132,"slug":4,"hasResults":10,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":136,"eligibilityCriteria":137,"healthyVolunteers":138,"sex":16,"minAge":49,"maxAge":139,"enrollmentInfo":140,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":142,"conditions":143,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":176},"100383878","NCT04278404","Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)","Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs","POPS or POP02","Inclusion Criteria:\n\n1. Participant is \\\u003C 21 years of age\n2. Parent\u002F Legal Guardian\u002F Adult Participant can understand the consent process and is willing to provide informed consent\u002FHIPAA:\n3. (a) Participant is receiving one or more of the study drugs of interest at the time of enrollment or (b) Participant is NOT receiving one or more of the study drugs of interest but is SARS-COV-2 positive within 60 days prior to enrollment\n\nExclusion Criteria:\n\n1. Participant has a known pregnancy\n\n   Below exclusion criteria apply only to:\n\n   Participants receiving one or more of the study drugs of interest at the time of enrollment, DOI administration or PK sampling: (Refer to DOI specific appendices for details on enrollment cohort specifications and additional eligibility criteria)\n2. Has had intermittent dialysis within previous 24 hours\n3. Has had a kidney transplant within previous 30 days\n4. Has had a liver transplant within previous 1 year\n5. Has had a stem cell transplant within previous 1 year\n6. Has had therapeutic hypothermia within previous 24 hours\n7. Has had plasmapheresis within the previous 24 hours\n8. Has a Ventricular Assist Device\n9. Has any condition which would make the participant, in the opinion of the investigator, unsuitable for the study",true,"20 Years",{"count":141,"type":20},5000,"The study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults in hopes to find the most safe and effective dose for children. The primary objective of this study is to evaluate the PK of understudied drugs currently being administered to children per SOC as prescribed by their treating provider.",[144,145,146,147,148,149,150,151,152,26,153,154,155,156,157,28,158,159,160,161,162,163,164,165,166],"Coronavirus Infection (COVID-19)","Pulmonary Arterial Hypertension","Urinary Tract Infections in Children","Hypertension","Pain","Hyperphosphatemia","Primary Hyperaldosteronism","Edema","Hypokalemia","Hemophilia","Menorrhagia","Insomnia","Pneumonia","Skin Infection","Asthma in Children","Bronchopulmonary Dysplasia","Adrenal Insufficiency","Fibrinolysis; Hemorrhage","Attention Deficit Hyperactivity Disorder","Multisystem Inflammatory Syndrome in Children (MIS-C)","Kawasaki Disease","Coagulation Disorder","Down Syndrome","2026-03-31",{"date":169,"type":34},"2026-04-06",{"date":171,"type":34},"2020-03-05",{"date":173,"type":20},"2027-07",{"name":175,"class":41},"Duke University",51,{"id":178,"slug":4,"hasResults":10,"nctId":179,"briefTitle":180,"officialTitle":181,"acronym":182,"eligibilityCriteria":183,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":184,"targetDuration":4,"studyType":52,"phases":186,"briefSummary":188,"conditions":189,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":200},"100441903","NCT05034432","The PIVATAL Study -Study of Ventricular Arrhythmia (VTA) Ablation in Left Ventricular Assist Device (LVAD) Patients","Prophylactic Intra-Operative Ventricular Arrhythmia Ablation in High-Risk LVAD Candidates (PIVATAL)","PIVATAL","Inclusion Criteria:\n\n* Age \\> 18 years\n* Presence of advanced cardiomyopathy (of all INTERMACS classification) and eligible for LVAD implant per the decision of the Heart Failure clinical team\n* Implanted cardioverter defibrillator (ICD) any time in past with remote monitoring or planned to undergo ICD (or ICM as an alternative, if an ICD cannot be implanted for a clinical reason) implant within the index hospitalization for LVAD implant\n* History of treated or monitored sustained (i.e., \\>30 seconds in duration ) VT or VF episode within the past 5 years.\n\nExclusion Criteria:\n\n* Past successful VTA ablation without recurrent VTA prior to LVAD implant (Patients who continue to experience VTA post ablation and pre LVAD implant qualify to be enrolled)\n* Participation in other clinical trials (observational registries are allowed with approval)\n* Unable or unwilling to provide informed consent",{"count":185,"type":20},100,[187],"PHASE4","To investigate the effect of VTA ablation at the time of LVAD implant to see if it can reduce the incidence of VTA after surgery",[28,190],"Cardiomyopathies","2026-03-19",{"date":193,"type":34},"2026-03-23",{"date":195,"type":34},"2022-05-27",{"date":197,"type":20},"2027-06-30",{"name":199,"class":41},"University of Rochester",19,{"id":202,"slug":4,"hasResults":10,"nctId":203,"briefTitle":204,"officialTitle":205,"acronym":4,"eligibilityCriteria":206,"healthyVolunteers":138,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":207,"targetDuration":4,"studyType":52,"phases":209,"briefSummary":210,"conditions":211,"keywords":215,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":219,"lastUpdatePostDateStruct":220,"startDateStruct":222,"completionDateStruct":224,"leadSponsor":226,"locationsCount":42},"100622802","NCT07388355","A Usability Study of a Multi-channel ECG Monitoring Device","WearLinq eWave Patch Study","Inclusion Criteria:\n\n* Adult \\>18 years old and able to consent\n* Capable of using a smartphone app\n* Willing to shave patch area if needed\n\nExclusion Criteria:\n\n* Planning to undergo an MRI during the study period\n* Known allergic reaction to adhesives or hydrogels or with family history of adhesive skin allergies, or any other dermatological conditional that could confound placement or results\n* Presence of pacemaker, ICD or other implanted electronic devices\n* Open wounds, lesions or infected or inflamed areas of skin at the placement site (left-center of chest\u002Fsternum)\n* Pregnant or intending to become pregnant during the course of the study",{"count":208,"type":20},500,[54],"This study it to evaluate the usability of the WearLinq eWave patch in a general adult population.",[212,213,28,214],"Healthy Adult Participants","Heart Disease","Cardiac",[216,119,217,218],"Electrocardiogram","EKG","Cardiac diagnostic","2026-01-29",{"date":221,"type":34},"2026-02-05",{"date":223,"type":20},"2026-02",{"date":225,"type":20},"2027-12",{"name":227,"class":100},"Wearlinq",{"id":229,"slug":4,"hasResults":10,"nctId":230,"briefTitle":231,"officialTitle":232,"acronym":233,"eligibilityCriteria":234,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":235,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":237,"conditions":238,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":219,"lastUpdatePostDateStruct":241,"startDateStruct":243,"completionDateStruct":245,"leadSponsor":247,"locationsCount":4},"100623128","NCT07392606","Validation of PET Questionnaire for Experience and Sustainability in Telemedicine. PET(Patient Experience in Telehealth)","Assessment of Patient Experience in Telemedicine: Validation of the Co-designed \"Patient Experience in Telehealth (PET)\" Questionnaire to Measure Experience and Assess Environmental, Economic and Organizational Impact.","PET","Inclusion Criteria:\n\n* Age ≥18 years\n* Receipt of at least one telemedicine service at FPG IRCCS\n* Provision of informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Cognitive or linguistic difficulties preventing comprehension of the questionnaire, in the absence of an available caregiver to provide assistance.\n* Exclusive use of telemonitoring services or asynchronous reporting, as the survey focuses on synchronous interactions (e.g., video consultation).",{"count":236,"type":20},200,"Background: Telemedicine adoption has expanded rapidly in recent years, creating new opportunities for access to care, particularly for frail patients or those with mobility limitations. However, the large-scale deployment of remote healthcare services has highlighted the lack of validated instruments to systematically and multidimensionally assess patients' subjective experience. Patient experience is recognized as a key indicator of quality of care, with direct implications for treatment adherence, appropriate use of digital health technologies, and the effectiveness of organizational care models.\n\nRationale: No instruments have been specifically validated in Italy to measure patient experience in telemedicine. In response, the Fondazione Policlinico Universitario A. Gemelli - Istituto di Ricovero e Cura a Carattere Scientifico (FPG IRCCS) developed, through a co-design process involving expert patients and healthcare professionals, the Patient Experience in Telehealth questionnaire (PET). The tool was designed to capture not only overall satisfaction, but also relational, informational, and organizational domains, as well as perceived economic and environmental impact.\n\nObjectives: The primary objective is psychometric validation of PET, assessing reliability and validity (construct, convergent, and discriminant). Secondary objectives include evaluating the perceived impact of telemedicine on care organization, patient-borne costs, and the environment, and exploring differences according to sociodemographic variables.\n\nMethods: This cross-sectional observational study will administer PET to at least 200 adult patients who received one or more telemedicine services at FPG IRCCS within the preceding three months. Content validity will be assessed by an expert panel. Descriptive analyses, exploratory factor analysis (EFA), confirmatory factor analysis (CFA), and reliability testing will be performed. A subgroup will complete a test-retest assessment after 7-14 days.\n\nHypothesis: PET is expected to demonstrate satisfactory psychometric properties, discriminate across different levels of patient experience, and capture the perceived organizational, economic, and environmental impacts of telemedicine in healthcare delivery.",[239,28,240],"IBD","Radiation Therapy Complication",{"date":242,"type":34},"2026-02-06",{"date":244,"type":20},"2026-02-01",{"date":246,"type":20},"2027-02-01",{"name":248,"class":41},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":250,"slug":4,"hasResults":10,"nctId":251,"briefTitle":252,"officialTitle":253,"acronym":254,"eligibilityCriteria":255,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":256,"targetDuration":4,"studyType":52,"phases":258,"briefSummary":259,"conditions":260,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":272,"lastUpdatePostDateStruct":273,"startDateStruct":274,"completionDateStruct":276,"leadSponsor":278,"locationsCount":280},"100544852","NCT06374277","Pharmacy-led Transitions of Care Intervention to Improve Medication Adherence","Pharmacy-led Transitions of Care Intervention to Address System-Level Barriers and Improve Medication Adherence in Socioeconomically Disadvantaged Populations","MedAAAction","Inclusion Criteria:\n\n* Medicaid or uninsured inpatients\n* 21 years or older\n* ≥2 of the complex chronic conditions during index admission or prescribed\u002Fusing ≥2 chronic medications for these conditions\n* Patients receiving chronic disease medications from the hospital pharmacy.\n* Patients will be eligible if they have multiple complex chronic conditions including diabetes, hypertension, high cholesterol, coronary artery disease, congestive heart failure, chronic lung disease, chronic kidney disease, arrhythmia, stroke, psychiatric disorders including depression and anxiety, or who are prescribed or using anticoagulants.\n\nExclusion Criteria:\n\n* Medicare and Medicaid dual eligible patients.\n* If the primary reason for the index admission is related to cancer, pregnancy, or a surgical procedure for an acute problem\n* If patients have diagnoses of active psychosis, substance abuse, or suicidal ideation during the index admission.\n* If the planned discharge location is not home.\n* If patients are part of an existing pharmacy discharge program.",{"count":257,"type":20},388,[54],"Socioeconomically disadvantaged populations with multiple chronic conditions have high rates of nonadherence to essential chronic disease medications after hospital discharge. Medication nonadherence after hospital discharge is significantly associated with increased mortality and higher rates of readmissions and costs among these patients. Major patient-reported barriers to essential medication use after hospital discharge among low-income individuals are related to social determinants of health (SDOH) and include: 1) financial barriers , 2) transportation barriers, and 3) system-level barriers. Although, medication therapy management services are important during care transitions, these services have not proven effective in improving medication adherence after hospital discharge, highlighting a critical need for innovative interventions. The Medication Affordability, Accessibility, and Availability in Care Transitions (Med AAAction) Study will test the effectiveness of a pharmacy-led care transitions intervention versus usual care through a pragmatic randomized controlled trial of 388 Medicaid and uninsured hospital in-patients with MCC from three large healthcare systems in Tennessee. The intervention will involve: 1) medications with zero copay, 2) bedside delivery then home delivery of medications, and 3) care coordination provided by certified pharmacy technicians\u002Fhealth coaches to assist with medication access, medication reconciliation, and rapid and ongoing primary care follow-up. We will examine the impact of the intervention during 12 months on 1) medication adherence (primary outcome) and 2) rapid primary care follow-up, 30-day readmissions, hospitalizations and emergency department visits, and costs. We will conduct key informant interviews to understand patient experience with the acre received during and after care transitions. By examining effectiveness of the intervention on outcomes including medication adherence, health care utilization, costs, and patient experience, this study will provide valuable results to health systems, payers, and policymakers to assist in future implementation and sustainability of the intervention for socioeconomically disadvantaged populations.",[261,147,262,263,264,265,266,28,267,268,269,270,271],"Diabetes","High Cholesterol\u002FHyperlipidemia","Coronary Artery Disease","Congestive Heart Failure","Chronic Lung Disease","Chronic Kidney Diseases","Stroke","Depression","Anxiety","Pulmonary Embolism","Heart Attack","2026-01-27",{"date":219,"type":34},{"date":275,"type":34},"2024-04-06",{"date":277,"type":20},"2028-01-31",{"name":279,"class":41},"University of Tennessee",2,{"id":282,"slug":4,"hasResults":10,"nctId":283,"briefTitle":284,"officialTitle":285,"acronym":286,"eligibilityCriteria":287,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":288,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":290,"conditions":291,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":292,"lastUpdatePostDateStruct":293,"startDateStruct":295,"completionDateStruct":297,"leadSponsor":299,"locationsCount":42},"100465144","NCT05336877","Aveir VR Coverage With Evidence Development Post-Approval Study","Aveir Single-Chamber Leadless Pacemaker Coverage With Evidence Development (ACED) Post-Approval Study","CED","The study cohort will include all Medicare patients with continuous claims data implanted with an Aveir VR leadless pacemaker or a full-system single-chamber ventricular transvenous pacemaker (from any manufacturer) in any US location\n\nInclusion Criteria:\n\nMedicare beneficiaries implanted with an Aveir VR leadless pacemaker on or after the study start date (i.e., the date of Aveir VR market approval) will be included in the study.\n\nOR\n\nMedicare beneficiaries implanted with a full system (e.g. lead and generator) single-chamber ventricular transvenous pacemaker on or after the study start date\n\nExclusion Criteria:\n\nNone",{"count":289,"type":20},8744,"The purpose of this coverage with evidence development (CED) study is to evaluate complications and long-term health outcomes of the single-chamber Aveir Single-Chamber Leadless Pacemaker device (Aveir VR LP).",[83,28,84],"2025-07-29",{"date":294,"type":34},"2025-07-31",{"date":296,"type":34},"2022-06-21",{"date":298,"type":20},"2028-01-01",{"name":99,"class":100},{"id":301,"slug":4,"hasResults":10,"nctId":302,"briefTitle":303,"officialTitle":304,"acronym":4,"eligibilityCriteria":305,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":306,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":308,"conditions":309,"keywords":310,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":313,"lastUpdatePostDateStruct":314,"startDateStruct":316,"completionDateStruct":317,"leadSponsor":319,"locationsCount":42},"100510912","NCT05932602","AVEIR DR Coverage With Evidence Development (CED) Study","The AVEIR DR Coverage With Evidence Development (DRIVE) Study","Inclusion Criteria:\n\n* Medicare beneficiaries implanted with an Aveir DR leadless pacemaker on or after the study start date (i.e., the date of Aveir DR market approval) will be included in the study.\n\nOR\n\nMedicare beneficiaries implanted with a full system (e.g. lead and generator) dual-chamber transvenous pacemaker on or after the study start date\n\nExclusion Criteria:\n\nNone",{"count":307,"type":20},2812,"The purpose of this coverage with evidence development (CED) study is to evaluate complications and long-term health outcomes of the dual chamber Aveir Leadless Pacemaker device (aka Aveir™ DR LP system).",[83,28,84],[311,87,88,312],"dual chamber","AV Block","2025-04-03",{"date":315,"type":34},"2025-04-06",{"date":95,"type":34},{"date":318,"type":20},"2030-05",{"name":99,"class":100},{"id":321,"slug":4,"hasResults":10,"nctId":322,"briefTitle":323,"officialTitle":324,"acronym":4,"eligibilityCriteria":325,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":326,"enrollmentInfo":327,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":329,"conditions":330,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":331,"lastUpdatePostDateStruct":332,"startDateStruct":334,"completionDateStruct":336,"leadSponsor":337,"locationsCount":42},"100548814","NCT06425887","Smartwatch Paroxysmal Arrhythmia Detection Compared with Holter","Smartwatch Paroxysmal Arrhythmia Detection Compared with Holter - a Multicenter Controlled Trial","Inclusion Criteria:\n\n1. All patients referred for out-patient Holter exam from age 18 - 80 years old\n2. The following indications for Holter exam will be allowed for recruitment\n\n   * Palpitation\n   * Pre-syncope\n   * Dizziness\n\nExclusion Criteria:\n\n1. Patients with a prior ECG diagnosis to explain the symptom\n2. Primary symptom is syncope\n3. Patient who has no clear indication for Holter exam\n4. Pregnant ladies\n5. Patients who failed to make a successful recording despite teaching attempts.\n6. Patients who cannot read English or Chinese version of consent.\n7. Anticipation of non-compliance with recording protocol.\n8. Patients who do not have a compatible smart phone (Android 9.0 or newer, or iOS15 or newer)\n9. Patients under custody","80 Years",{"count":328,"type":20},185,"The lifetime risk for development of atrial fibrillation, the commonest sustained arrhythmia in adults, is estimated to be 24%-27% for individuals of 40 years or older. Previous work showed that annual new diagnosis of AF is 11000-26000 in Hong Kong. Other arrhythmia such as supraventricular arrhythmia or premature beats were also common and of clinical significance.\n\n12-lead ECG is a first line investigation for patients with suspected paroxysmal arrhythmia, but it has a low diagnostic yield with its 10-30 seconds recordings. 24-hour Holter exam is the usual next step of diagnosis. The diagnostic yield of Holter varies according to indication but is generally low at 1%-12%. This is because paroxysmal arrhythmia may not happen every day. In addition, even if arrhythmia is picked up in Holter, patient may not register the symptom, making the symptom arrhythmia correlation problematic.\n\nDespite limitations, the demand for Holter exam is still high. In Prince of Wales Hospital, a tertiary referral centre with a catchment of about 1 million populations, the waiting time for a routine Holter exam is 3 years.\n\nSmartwatch has gained popularity over past years as an adjunct to smartphone. Latest generations of smartwatch were equipped with wearer-initiated ECG rhythm strip recording capabilities. Smartwatch has evolved to become a health tracker with arrhythmia detection capabilities. It was found to be a useful tool for atrial fibrillation screening in general population. Other arrhythmias, such as supraventricular tachycardia, premature beats, and abnormal ECG patterns associated with sudden cardiac death could also be detected with smartwatch ECG recordings. Apple Heart study was the largest study utilizing smartwatch for arrhythmia detection. The general population was screened for atrial fibrillation using irregular pulse algorithm. The study found a 84% concordance rate between irregular pulse notification and ECG patches.\n\nTherefore, investigators propose to conduct a study to compare its diagnostic yield with Holter, in patients with suspected arrhythmia and see if smartwatch recording following a systematic protocol for four-weeks will have better arrhythmia diagnosis yield than a 24-hour Holter exam.",[28],"2024-10-24",{"date":333,"type":34},"2024-10-28",{"date":335,"type":34},"2024-07-01",{"date":33,"type":20},{"name":338,"class":41},"Chinese University of Hong Kong",{"id":340,"slug":4,"hasResults":10,"nctId":341,"briefTitle":342,"officialTitle":343,"acronym":344,"eligibilityCriteria":345,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":346,"targetDuration":4,"studyType":52,"phases":348,"briefSummary":349,"conditions":350,"keywords":351,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":356,"lastUpdatePostDateStruct":357,"startDateStruct":359,"completionDateStruct":361,"leadSponsor":363,"locationsCount":42},"100545953","NCT06388629","Epicardial Access Study With Rook","Epicardial Access Study With Rook (EASY-R)","EASY-R","Inclusion Criteria:\n\n1. Patient is clinically indicated to undergo a procedure that requires percutaneous access to the normal, non-distended, pericardial space.\n2. Patient is willing and able to provide written informed consent.\n\nExclusion Criteria:\n\n1. Subject is younger than 18 years of age\n2. Previous cardiac surgery\n3. Myocardial infarction within 4 weeks prior to procedure\n4. Class IV NYHA (New York Heart Association) heart failure symptoms\n5. Subject with an active systemic infection\n6. Known carotid artery stenosis greater than 80%\n7. Presence of thrombus in the left atrium\n8. Congenital absence of a pericardium\n9. Coagulopathy\n10. Hemodynamic Instability\n11. Acute conditions (i.e. electrolyte abnormality, acute ischemia, drug toxicity)\n12. Severe hepatic dysfunction or enlargement\n13. Subject has Body Mass Index \\> 40\n14. Life expectancy less than 6 months\n15. Subject is pregnant\n16. Subject is currently participating in another investigational drug or device study that clinically interferes with the endpoints of this study\n17. Subject has known or suspected allergy to contrast media\n18. Subject is known to have pericardial fibrosis, pericardial adhesions, or prior failed epicardial access",{"count":347,"type":20},40,[54],"The goal of this clinical trial is to test how how effective the Circa Scientific Rook® Epicardial Access Kit is at gaining guidewire access to the outside surface of the heart (epicardium). In addition the safety of the device will be compared to the available data for alternative methods of epicardial access.\n\nParticipants will receive treatment with the subject device during the course of a typical epicardial electrophysiology procedure.",[28],[352,353,354,355],"Electrophysiology","Pericardial Access","Epicardial Access","EP","2024-08-19",{"date":358,"type":34},"2024-08-21",{"date":360,"type":34},"2023-12-17",{"date":362,"type":20},"2024-10-15",{"name":364,"class":100},"Circa Scientific, Inc.",{"id":366,"slug":4,"hasResults":10,"nctId":367,"briefTitle":368,"officialTitle":369,"acronym":4,"eligibilityCriteria":370,"healthyVolunteers":138,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":371,"targetDuration":4,"studyType":52,"phases":373,"briefSummary":374,"conditions":375,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":378,"lastUpdatePostDateStruct":379,"startDateStruct":381,"completionDateStruct":383,"leadSponsor":385,"locationsCount":42},"100536593","NCT06266845","Efficacy of Gamification With Escape-Room for Arrhythmia Identification in Critical Patients","Efficacy of Gamification With Escape-Room for Arrhythmia Identification in Critical Patients: an Experiment With Nursing Undergraduates","Inclusion Criteria:\n\n* Students enrolled in the undergraduate nursing program who have successfully completed the course related to adult and elderly health.\n\nExclusion Criteria:\n\n* Healthcare professionals, including those participants who, at any point during the research stages, choose to withdraw or who have not completed\u002Fparticipated in one of the study phases.",{"count":372,"type":20},53,[54],"Introduction: Health education provided through the escape-room is still a recent approach in educational methodology and tends to be a strategy that benefits nursing students, particularly in gaining knowledge and skills. However, few studies have explored the use of both in-person and virtual escape-room as an educational methodology in nursing. Objective: To assess the effectiveness of the gamification strategy through the in-person escape-room model compared to the virtual model in enhancing cognitive and affective competencies for recognizing cardiac arrhythmias in critical care patients within the nursing field. Method: A randomized clinical trial to be conducted with nursing students from higher education institutions in the Federal District, Brazil. Students will undergo a theoretical class on cardiac arrhythmias in critical patients and will then be randomized to experience either the in-person or virtual escape-room scenario. Knowledge tests, the Depression, Anxiety, and Stress Scale, Satisfaction and Self-confidence Scale in nursing management learning, and perceived gains will be administered pre and post-intervention. Results with p≤0.05 will be considered significant. Expected Results: It is anticipated that this study will contribute to the enhancement and broadening of cognitive and affective competencies in nursing students, improving the quality of care through an active educational strategy like the escape-room, and consequently reducing costs for the Unified Health System by minimizing errors in recognizing clinical changes in critical patients. Additionally, the study aims to address gaps in understanding the use of educational escape-rooms in the field of nursing.",[28,376,377],"Health Education","Escape-Room","2024-07-08",{"date":380,"type":34},"2024-07-10",{"date":382,"type":34},"2024-03-04",{"date":384,"type":20},"2024-12-31",{"name":386,"class":41},"University of Brasilia",{"id":388,"slug":4,"hasResults":10,"nctId":389,"briefTitle":390,"officialTitle":390,"acronym":4,"eligibilityCriteria":391,"healthyVolunteers":10,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":392,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":394,"conditions":395,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":396,"lastUpdatePostDateStruct":397,"startDateStruct":399,"completionDateStruct":400,"leadSponsor":402,"locationsCount":42},"100553494","NCT06486818","Clinical Predictors of Short Term Outcomes of Ablation of Idiopathic Monomorphic PVCs","Inclusion Criteria:\n\n* patients with idiopathic monomorphic PVCs\n\nExclusion Criteria:\n\n* patients with heart failure",{"count":393,"type":20},28,"Clinical predictors of successful Pvcs ablation",[28],"2024-06-27",{"date":398,"type":34},"2024-07-05",{"date":335,"type":20},{"date":401,"type":20},"2025-12-30",{"name":403,"class":41},"Assiut University",{"id":405,"slug":4,"hasResults":10,"nctId":406,"briefTitle":407,"officialTitle":408,"acronym":409,"eligibilityCriteria":410,"healthyVolunteers":138,"sex":16,"minAge":17,"maxAge":326,"enrollmentInfo":411,"targetDuration":412,"studyType":22,"phases":4,"briefSummary":413,"conditions":414,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":418,"lastUpdatePostDateStruct":419,"startDateStruct":421,"completionDateStruct":423,"leadSponsor":425,"locationsCount":42},"100544672","NCT06371937","iPSC Biobank of Biomarkers Diversity in Cardiovascular Disease","Blood Biomarkers From Ethnically Diverse Cardiovascular Patients","INFERENCE","Inclusion Criteria:\n\n* Adult (18 to 80 years of age)\n* Cardiovascular Disease (CVD)\n* Cerebrovascular Disease (CBD)\n* Peripheral Vascular Disease (PVD)\n* Inherited Arrhythmias\n* Cardiomyopathies\n* Congenital Heart Disease (CHD)\n* Aortopathy\n* Hypertension\n* Cardiometabolic Disease (CMD)\n\nExclusion Criteria:\n\n* Younger than 18 years of age.\n* Patients not able to provide consent.",{"count":236,"type":20},"10 Years","The Investigators will create a clinical database and a Biobank of stem cells derived from the blood of participants with cardiovascular disease. The Investigators will recruit participants from diverse racial and ethnic backgrounds with equal representation from both sexes. The Investigators expect to create stem cells and analyze the blood for protein biomarkers and genetic causes of cardiovascular disease. The stem cell biobank and clinical data will be a powerful tool for studying cardiovascular disease.",[415,28,190,26,416,25,417],"Cardiovascular Diseases","Cerebrovascular Accident","Cardiometabolic Syndrome","2024-05-28",{"date":420,"type":34},"2024-05-29",{"date":422,"type":34},"2024-05-01",{"date":424,"type":20},"2033-06-30",{"name":426,"class":41},"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's",{"id":428,"slug":4,"hasResults":10,"nctId":429,"briefTitle":430,"officialTitle":431,"acronym":432,"eligibilityCriteria":433,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":434,"enrollmentInfo":435,"targetDuration":4,"studyType":52,"phases":437,"briefSummary":438,"conditions":439,"keywords":440,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":443,"lastUpdatePostDateStruct":444,"startDateStruct":446,"completionDateStruct":447,"leadSponsor":448,"locationsCount":4},"100548579","NCT06422832","Remote Monitoring To Identify Worsening Heart Failure The REMOTI-HF Randomized Clinical Trial","Remote Monitoring To Identify Worsening Heart Failure: The REMOTI-HF Randomized Clinical Trial","REMOTI-HF","Inclusion Criteria:\n\n* Possession of an implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy (CRT) device that is compatible with the HeartLogic or TriageHF algorithms.\n* Left ventricular ejection fraction at the time of device implantation must be equal to or less than 35%.\n\nExclusion Criteria:\n\n* Younger than 18 years old or older than 85 years old.\n* Unable to be contacted when out of the hospital.\n* Presence of severe cognitive impairment.\n* Currently on the heart transplant waiting list","85 Years",{"count":436,"type":20},270,[54],"Heart failure, characterized by high mortality and morbidity rates, frequent hospital admissions, and prolonged stays in cardiology wards, significantly impacts patients' quality of life.\n\nThe REMOTI-HF is a single-center randomized controlled trial designed to assess the impact of remote monitoring, utilizing the HeartLogic and TriageHF algorithms, in patients with heart failure with implantable cardioverter defibrillator or cardiac resynchronization therapy. The primary endpoints include mortality, hospital admissions related to heart failure, and visits for worsening heart failure.\n\nMoreover, we will explore the full capabilities of these algorithms, by analysing the association of physical activity, measured by the devices, with the same key outcomes. Additionally, the research will explore the relationship between the absolute values provided by the algorithms and NT-proBNP values.",[26,28],[26,114,441,442],"ICD","CRT","2024-05-15",{"date":445,"type":34},"2024-05-21",{"date":335,"type":20},{"date":33,"type":20},{"name":449,"class":41},"Unidade Local de Saúde de Coimbra, EPE",{"id":451,"slug":4,"hasResults":10,"nctId":452,"briefTitle":453,"officialTitle":454,"acronym":455,"eligibilityCriteria":456,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":457,"targetDuration":459,"studyType":22,"phases":4,"briefSummary":460,"conditions":461,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":464,"lastUpdatePostDateStruct":465,"startDateStruct":467,"completionDateStruct":469,"leadSponsor":471,"locationsCount":42},"100422116","NCT04776642","Biobank for \"Arrhythmia and Conduction Disorders: TowArd Pathophysiology Based Treatment\"","\"Arrhythmia and Conduction Disorders: TowArd Pathophysiology Based Treatment\" ADAPT Biobank","ADAPT","Inclusion criteria:\n\n* Patients visiting the AMC outpatient clinic\n* Patients included in an ongoing clinical trial linked to this biobank. Studies are listed under point \"Groups and interventions\" and include:\n\n  * MARK AF\n  * INDICO AF\n  * PREDICT AF\n  * WEIGHTLOSS AF\n  * MAD AF\n* Patients included in future clinical trial linked to this biobank. Studies may be linked to this biobank that investigates prevalent or incident cardiac arrhythmias.\n* Cardiac arrhtymias are defined as\n\n  * Supraventricular tachycardia, among which the most common are:\n\n    * Atrial Fibrillation (AF)\n    * Atrial Tachycardia (AT)\n    * Atrial Flutter (AFL)\n    * Atrioventricular Nodal Reentrant Tachycardia (AVNRT)\n    * Atrioventricular Reentrant Tachycardia (AVRT)\n  * Ventricular tachycardia, among which the most common are:\n\n    * Ventricular Tachycardia (VT)\n    * Ventricular Flutter (VFL)\n    * Ventricular Fibrillation (VF)\n  * Bradycardia:\n\n    * Sinus Node Dysfunction\n    * AV Node Dysfunction\n    * Interventricular Conduction Disorder\n  * Arrhythmogenic cardiomyopathies, among which the most common are:\n\n    * Dilated Cardiomyopathy\n    * Restrictive Cardiomyopathy\n    * Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)\n\nExclusion criteria (shared for all studies):\n\n* Age \\\u003C 18\n* Unable or unwilling to comply with study procedures\n* Pregnancy or of childbearing potential without adequate contraception\n* NYHA class IV heart failure symptoms or left ventricular ejection fraction \\\u003C35%.",{"count":458,"type":20},1000,"5 Years","The 'ADAPT' Biobank is a collection of body material and data from patients with or at risk of cardiac arrhythmias who underwent or will undergo (non-) invasive treatment for this disease. Its main objective is to obtain a comprehensive collection of patient information and material to facilitate research and gain better insight into the complex pathophysiology of the different arrhythmias, the multifactorial process, the heterogeneity in clinical presentation, and prognosis.\n\nBodily material is used for biochemical marker assessments, histological and molecular analyses for research in cardiac arrhythmias.",[28,462,463],"Conduction Disorder","Pathophysiology","2024-01-24",{"date":466,"type":34},"2024-01-25",{"date":468,"type":34},"2014-12-18",{"date":470,"type":20},"2030-01",{"name":472,"class":41},"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)",""]